tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX), Axsome Therapeutics (AXSM) and Prometheus Biosciences (RXDX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MacroGenics (MGNXResearch Report), Axsome Therapeutics (AXSMResearch Report) and Prometheus Biosciences (RXDXResearch Report) with bullish sentiments.

MacroGenics (MGNX)

BTIG analyst Kaveri Pohlman maintained a Buy rating on MacroGenics yesterday and set a price target of $50.00. The company’s shares closed last Tuesday at $7.75, close to its 52-week low of $6.92.

According to TipRanks.com, Pohlman has 0 stars on 0-5 stars ranking scale with an average return of -25.1% and a 7.0% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Checkmate Pharmaceuticals, and Oncternal Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MacroGenics with a $29.25 average price target, implying a 290.5% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $24.00 price target.

See the top stocks recommended by analysts >>

Axsome Therapeutics (AXSM)

BTIG analyst Robert Hazlett maintained a Buy rating on Axsome Therapeutics on May 2 and set a price target of $62.00. The company’s shares closed last Tuesday at $35.84.

According to TipRanks.com, Hazlett is a 1-star analyst with an average return of -1.0% and a 31.3% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and Paratek Pharmaceuticals.

Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $80.88, a 135.0% upside from current levels. In a report issued on April 25, Mizuho Securities also maintained a Buy rating on the stock with a $51.00 price target.

Prometheus Biosciences (RXDX)

BTIG analyst Julian Harrison reiterated a Buy rating on Prometheus Biosciences yesterday and set a price target of $62.00. The company’s shares closed last Tuesday at $30.48.

According to TipRanks.com, Harrison has 0 stars on 0-5 stars ranking scale with an average return of -30.8% and a 22.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Aerovate Therapeutics, and United Therapeutics.

Prometheus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $53.60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MGNX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed